IOnctura Awarded EUR17.5 Million Funding From The EIC Accelerator For Clinical Development Of Novel Pancreatic Cancer Therapy

/in

Funding will support iOnctura’s clinical program for IOA-289, a first-in-class autotaxin inhibitor for the treatment of cancer Amsterdam, The Netherlands, 20 December 2022 – iOnctura BV, a clinical-stage biotech developing novel cancer therapies, announces today that it has been granted EUR17.5 million funding from the European Investment Council’s (EIC) Accelerator Program to develop IOA-289 for pancreatic cancer. The EIC’s funding […]

Read more

Verona Pharma Announces Ensifentrine Meets Primary and Key Secondary Endpoints in Phase 3 ENHANCE-1 Trial for COPD

/in

Statistically significant improvements in lung function, symptoms and quality of life 36% reduction in rate of exacerbations over 24 weeks Well tolerated safety profile over 48 weeks NDA submission planned for 1H 2023 Conference call today at 8:30 a.m. EST / 1:30 p.m. GMT LONDON and RALEIGH, N.C., Dec. 20, 2022 (GLOBE NEWSWIRE) — Verona […]

Read more

Cutting-edge protein design project to join BioInnovation Institute’s Bio Studio program

/in

BioInnovation Institute (BII), an international enterprise foundation with a non-profit objective incubating and accelerating world-class life science research, announces today that it has accepted a new project into its Bio Studio program. Based on recent breakthroughs in Artificial Intelligence (AI) and protein design, the project is creating a new class of therapeutic proteins to modulate […]

Read more

MinervaX announces 72M EUR financing to advance development of novel vaccine against Group B Streptococcus

/in

Financing from new investors Trill Impact Ventures and Pureos Bioventures as well as existing investors Backing from European Investment Bank Planning for Phase 3 clinical development of novel GBS vaccine Copenhagen, Denmark, 15 December 2022 – MinervaX ApS, a privately held Danish biotechnology company developing a novel vaccine against Group B Streptococcus (GBS), today announces the […]

Read more

Alchemab Therapeutics | The Chain Podcast

/in

THE CHAIN PODCAST Our Co-Founder and CSO Jane Osbourn was delighted to speak with her longtime friend Ahuva Nissim, antibody and therapeutic engineering professor at William Harvey Research Institute, Queen Mary University of London, about the career path that took her from studying molecular biology and building human phage libraries to developing therapeutics with convergent […]

Read more
© Optimum Strategic Communications.